Stifel Nicolaus Keeps Their Buy Rating on DRI Healthcare (DHT.UN)
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Justin Keywood has maintained a Buy rating on DRI Healthcare (DHT.UN) with a price target of C$22.00. The analyst focuses on the Healthcare sector and has an average return of -1.5% with a 50.94% success rate on stock recommendations. The current analyst consensus for DRI Healthcare is a Moderate Buy, with an average price target of C$21.50.
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on DRI Healthcare today and set a price target of C$22.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, NervGen Pharma, and DRI Healthcare. According to TipRanks, Keywood has an average return of -1.5% and a 50.94% success rate on recommended stocks.
Currently, the analyst consensus on DRI Healthcare is a Moderate Buy with an average price target of C$21.50.